Login to Your Account

GSK Spinout NeRRe Begins with $19M, Neurokinin Drugs

By Nuala Moran
Staff Writer

Friday, December 21, 2012
A third spinout has emerged from GlaxoSmithKline plc's neurosciences research portfolio, with the formation of NeRRe Therapeutics Ltd. The new company begins life with a portfolio of four neurokinin-1 receptor antagonists – of which two are ready for Phase II.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription